Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Cold Intolerance
NCT04917731Phase 1Unknown
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2021
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cold intolerance comparing Botox with Placebo (2 arms). Primary endpoints: Cold Intolerance Severity Score at 12 weeks and Quick Disabilities of the Arm, Shoulder and Hand at 3 months. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
cold intolerance
Beyond the preview
Go deeper on NCT04917731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04917731.